These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27180963)

  • 21. Endoplasmic reticulum-associated degradation: exceptions to the rule.
    Schmitz A; Herzog V
    Eur J Cell Biol; 2004 Oct; 83(10):501-9. PubMed ID: 15679096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Hydroxy Groups in the A-Ring on the Anti-proteasome Activity of Flavone.
    Nakamura K; Yang JH; Sato E; Miura N; Wu YX
    Biol Pharm Bull; 2015; 38(6):935-40. PubMed ID: 25810454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid-β secretion, generation, and lysosomal sequestration in response to proteasome inhibition: involvement of autophagy.
    Agholme L; Hallbeck M; Benedikz E; Marcusson J; Kågedal K
    J Alzheimers Dis; 2012; 31(2):343-58. PubMed ID: 22555375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chaperone activities of the 26S and 20S proteasome.
    Yano M; Kanesaki Y; Koumoto Y; Inoue M; Kido H
    Curr Protein Pept Sci; 2005 Apr; 6(2):197-203. PubMed ID: 15853655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity-based probes for the multicatalytic proteasome.
    Hewings DS; Flygare JA; Wertz IE; Bogyo M
    FEBS J; 2017 May; 284(10):1540-1554. PubMed ID: 28107776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bilirubin neurotoxicity is associated with proteasome inhibition.
    Huang H; Guo M; Liu N; Zhao C; Chen H; Wang X; Liao S; Zhou P; Liao Y; Chen X; Lan X; Chen J; Xu D; Li X; Shi X; Yu L; Nie Y; Wang X; Zhang CE; Liu J
    Cell Death Dis; 2017 Jun; 8(6):e2877. PubMed ID: 28617443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting proteasomes with natural occurring compounds in cancer treatment.
    Cecarini V; Cuccioloni M; Mozzicafreddo M; Bonfili L; Angeletti M; Eleuteri AM
    Curr Cancer Drug Targets; 2011 Mar; 11(3):307-24. PubMed ID: 21265733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation.
    Choi WH; de Poot SA; Lee JH; Kim JH; Han DH; Kim YK; Finley D; Lee MJ
    Nat Commun; 2016 Mar; 7():10963. PubMed ID: 26957043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (Immuno)proteasomes as therapeutic target in acute leukemia.
    Cloos J; Roeten MS; Franke NE; van Meerloo J; Zweegman S; Kaspers GJ; Jansen G
    Cancer Metastasis Rev; 2017 Dec; 36(4):599-615. PubMed ID: 29071527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
    Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
    Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative protein damage and the proteasome.
    Grimm S; Höhn A; Grune T
    Amino Acids; 2012 Jan; 42(1):23-38. PubMed ID: 20556625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An in silico model of the ubiquitin-proteasome system that incorporates normal homeostasis and age-related decline.
    Proctor CJ; Tsirigotis M; Gray DA
    BMC Syst Biol; 2007 Mar; 1():17. PubMed ID: 17408507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel crosstalk between two major protein degradation systems: regulation of proteasomal activity by autophagy.
    Wang XJ; Yu J; Wong SH; Cheng AS; Chan FK; Ng SS; Cho CH; Sung JJ; Wu WK
    Autophagy; 2013 Oct; 9(10):1500-8. PubMed ID: 23934082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ubiquitins, proteasomes, sumoylation and therapeutic application today and in future for cancer and other diseases. I. Ubiquitin-proteasome system and the transcription factor NF-kappaB].
    Fuchs O; Neuwirtová R
    Vnitr Lek; 2006 Apr; 52(4):371-8. PubMed ID: 16755993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasome system of protein degradation and processing.
    Sorokin AV; Kim ER; Ovchinnikov LP
    Biochemistry (Mosc); 2009 Dec; 74(13):1411-42. PubMed ID: 20210701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crosstalk between autophagy and proteasome protein degradation systems: possible implications for cancer therapy.
    Wojcik S
    Folia Histochem Cytobiol; 2013; 51(4):249-64. PubMed ID: 24497130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes.
    Xin BT; de Bruin G; Huber EM; Besse A; Florea BI; Filippov DV; van der Marel GA; Kisselev AF; van der Stelt M; Driessen C; Groll M; Overkleeft HS
    J Med Chem; 2016 Aug; 59(15):7177-87. PubMed ID: 27438186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Localized Proteasomal Degradation: From the Nucleus to Cell Periphery.
    Guo X
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the ubiquitin-proteasome system in brain ischemia: friend or foe?
    Caldeira MV; Salazar IL; Curcio M; Canzoniero LM; Duarte CB
    Prog Neurobiol; 2014 Jan; 112():50-69. PubMed ID: 24157661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.